Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nishtar Medical University | OTHER |
Not provided
Not provided
Not provided
This study aimed to fill this gap by comparing the effectiveness of intravenous magnesium sulfate versus terbutaline in children with acute asthma exacerbations, providing evidence-based guidance for clinicians in emergency settings.
Despite the established roles of both magnesium sulfate and terbutaline in the management of severe asthma exacerbations, there is limited comparative data on their efficacy and safety in the pediatric population. Understanding the relative benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IV Magnesium Sulfate | Experimental | Magnesium sulfate, a smooth muscle relaxant, has been shown to have bronchodilatory effects by inhibiting calcium influx into smooth muscle cells. |
|
| IV Terbutaline | Experimental | Terbutaline, a beta-2 agonist, is used intravenously to provide systemic bronchodilation when inhaled bronchodilators are not effective. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Magnesium Sulphate infusion | Drug | Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Post-treatment PEFR | Post-treatment, children response to treatment was measured by noting PEFR | 4 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Oxygen Saturation | Post-treatment, oxygen saturation was measured using Spirometry | 4 hours |
| Heart Rate | Post-treatment, heart rate was measured |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arif Zulqarnain, FCPS | Department of Pediatrics, Nishtar Hospital, Multan, Pakistan | Study Director |
| Muhammad Salman, FCPS | Department of Pediatrics, Nishtar Hospital, Multan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nishtar Hospital | Multan | Punjab Province | Pakistan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Terbutaline Infusion | Drug | Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours |
|
| 4-hours |
| Respiratory rate | Post-treatment, heart rate was measured. | 4 hours |
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012130 | Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided